Literature DB >> 27428830

Burden of costs associated with heparin-induced thrombocytopenia: is time to remove unfractionated heparin from the drug formularies in medical institutions?

Marco Zuin1, Claudio Picariello2, Lina Marcantoni2, Loris Roncon2.   

Abstract

Entities:  

Year:  2016        PMID： 27428830      PMCID： PMC4930522          DOI： 10.21037/atm.2016.05.60

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  7 in total

1.  Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Authors:  Robert A Fowler; Nicole Mittmann; William Geerts; Diane Heels-Ansdell; Michael K Gould; Gordon Guyatt; Murray Krahn; Simon Finfer; Ruxandra Pinto; Brian Chan; Orges Ormanidhi; Yaseen Arabi; Ismael Qushmaq; Marcelo G Rocha; Peter Dodek; Lauralyn McIntyre; Richard Hall; Niall D Ferguson; Sangeeta Mehta; John C Marshall; Christopher James Doig; John Muscedere; Michael J Jacka; James R Klinger; Nicholas Vlahakis; Neil Orford; Ian Seppelt; Yoanna K Skrobik; Sachin Sud; John F Cade; Jamie Cooper; Deborah Cook
Journal:  JAMA       Date:  2014-11-26       Impact factor: 56.272

Review 2.  CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.

Authors:  Andreas Greinacher
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

3.  End of the road for heparin thromboprophylaxis.

Authors:  Lori-Ann Linkins
Journal:  Blood       Date:  2016-04-21       Impact factor: 22.113

Review 4.  Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R G Junqueira; Edson Perini; Raphael R M Penholati; Maria G Carvalho
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

5.  Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.

Authors:  Nadine Martel; James Lee; Philip S Wells
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

6.  Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program.

Authors:  Kelly E McGowan; Joy Makari; Artemis Diamantouros; Claudia Bucci; Peter Rempel; Rita Selby; William Geerts
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

7.  Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.

Authors:  Luke Bamber; Dominic Muston; Euan McLeod; Anne Guillermin; Julia Lowin; Raj Patel
Journal:  Thromb J       Date:  2015-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.